Study (ref) | Disease | No. Patients | Age | Median age | Regimen | CR % | ED % | CT % |
---|
CALGB 8321 [30] | AML | 326 | 15-83 | NA | DNR (45 mg/m2) +Ara-C | 61 | 151 | NR |
ECOG [7] | AML | 582 | 17-60 | 48 | DNR (45 mg/m2) +Ara-C DNR (90 mg/m2) +Ara-C | 57 71 | 4.51 5.51 | 7.2 7.9 |
SALR [5] | AML | 2767 | 16-97 | 72 | anthracycline + Ara-C | 65 | 102 | NR |
HOVON and SAKK [31] | AML | 813 | 60-83 | 67 | DNR (45 mg/m2) +Ara-C DNR (90 mg/m2) +Ara-C | 54 64 | 112 122 | NR |
CAG | AML | 327 | 18-88 | NA | CAG | 57 | 9.03 | 2.8 |
Fenaux [33] | MDS | 358 | 38-88 | 69 | Azacitidine CCR | 17 8 | 114 94 | NR |
Kantarjian [34] | MDS | 510 | 17-88 | 63 | TA/FA/CAT/IA/DA | 55 | 175 | NR |
CAG | MDS | 215 | 26-78 | NA | CAG | 45.7 | 4.83 | 3.1 |
- Abbreviations: AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; Ref: references; NR: not reported; CR: complete remission; NA: not available; ED: early death; CT: cardiotoxicity; DNR: daunorubicin; Ara-C: cytarabine; 3+7: anthracycline plus cytarabine; CAG: cytarabine, aclarubicin and G-CSF; CCR: conventional care regimen; TA: Topotecan plus Ara-C; FA: Fludarabine plus Ara-C; CAT: Topotecan plus Ara-C plus cyclophosphamide; DA/IA: daunorubicin or idarubicin plus Ara-C; CALGB: Cancer and Leukemia Group B; ECOG: Eastern Cooperative Oncology Group; SALR: Swedish Acute Leukemia Registry; HOVON: Leukemia Working Group of the Dutch-Belgian Cooperative Trial Group for Hematology-Oncology; SAKK: Swiss Group for Clinical Cancer Research;
- Superscript numerical indicates the definitions of early death from different studies. 1: induction mortality (time frame not specified); 2: mortality within 30 days from diagnosis; 3: mortality within the first 8 weeks of induction treatment; 4: mortality during first 3 months; 5: mortality within 7 weeks of induction therapy.